Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda’s Zasocitinib Gets FDA Priority Review in Plaque Psoriasis
Takeda Pharmaceutical said on September 14 that the US FDA has accepted its new drug application for zasocitinib (TAK-279), an oral tyrosine kinase 2 (TYK2) inhibitor, under priority review for the treatment of adults with moderate-to-severe plaque psoriasis. The filing…
To read the full story
Related Article
- Takeda’s Zasocitinib Beats Sotyktu in PIII Psoriasis Trial
June 15, 2026
- Takeda’s Zasocitinib Logs Positive Results in Global PIII Psoriasis Trials
March 31, 2026
- Takeda Targets Psoriasis Market with Zasocitinib, Touts Edge in TYK2 Selectivity
March 4, 2026
- Takeda’s TYK2 Inhibitor Scores PIII Win in Psoriasis Trials
December 19, 2025
BUSINESS
- Takeda’s Zasocitinib Gets FDA Priority Review in Plaque Psoriasis
September 15, 2026
- Eisai Teams with Osaka Prefecture on Dementia, MCI Awareness
September 15, 2026
- Enhertu PFS Hits 14.3 Months in PIII for 1st-Line NSCLC
September 15, 2026
- Asahi Kasei Starts Pediatric Cresemba PII in Japan
September 15, 2026
- Santen Files Myopia Drug Ryjusea in China
September 15, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…